GlassScriptPhysician profile
Padma Bala Hari
NPI 1518920545
$4,396.84
in general payments reported to CMS, 2019-2025
34 companies · $554 in 2025
The $554 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,134 · 2020: $354 · 2021: $324 · 2022: $206 · 2023: $761 · 2024: $1,064 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,378.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $559.55 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Janssen Pharmaceuticals, INC | $483.05 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $456.13 | 2019-2025 | |
| Amgen INC. | $313.54 | 2019-2022 | |
| Pfizer INC. | $301.15 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $274.93 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.58 | 2019-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $236.45 | 2019-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $183.39 | 2019-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $175.97 | 2019-2023 | |
| Celgene Corporation | $132.04 | 2023-2024 | Camzyos |
| Esperion Therapeutics, INC. | $128.63 | 2021-2023 | Nexletol |
| Amarin Pharma, INC. | $123.65 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $118.37 | 2021-2024 | Verquvo |
| Cequr Corporation | $108.96 | 2025 | Cequr Simplicity |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $64.23 | 2019-2025 | Evkeeza |
| Edwards Lifesciences Corporation | $51.59 | 2019 | |
| Heartflow, INC. | $45.48 | 2023-2025 | Ffrct |
| Novo Nordisk INC | $41.69 | 2024-2025 | Ozempic, Wegovy |
| Kiniksa Pharmaceuticals, LTD. | $39.90 | 2023 | Arcalyst |
| Impulse Dynamics (USA) INC. | $33.35 | 2023 | Optimizer |
| Actelion Pharmaceuticals US, INC. | $33.04 | 2019 | |
| Abiomed | $31.21 | 2024 | Impella |
| Smith+Nephew, INC. | $21.85 | 2024 | Pico, Renasys Touch |
| Alnylam Pharmaceuticals INC. | $21.45 | 2025 | Onpattro |
| Abbott Laboratories | $20.40 | 2019 | |
| Biosense Webster, INC. | $19.81 | 2024 | Carto 3 |
| Kiniksa Pharmaceuticals International, Plc | $18.67 | 2024 | Arcalyst |
| Angiodynamics, INC. | $17.18 | 2023 | Angiovac |
| Philips North America LLC | $16.95 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $15.69 | 2023 | Inpefa |
| Kestra Medical Technology Services, INC. | $14.53 | 2024 | Assure Wcd |
| Cleerly, INC. | $14.43 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Bardy Diagnostics, INC. | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Padma Hari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.